NovaBridge Biosciences (NBP) Income towards Parent Company (2019 - 2025)
NovaBridge Biosciences (NBP) reported Income towards Parent Company of -$72.9 million for Q4 2025, down 112.02% year-over-year from $606.2 million in Q4 2024, and down 967.05% quarter-over-quarter from -$6.8 million in Q3 2025.
NovaBridge Biosciences (NBP) Income towards Parent Company (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 5 years of Income towards Parent Company data on file, last reported at -$72.9 million in Q4 2025.
- Income towards Parent Company for Q4 2025 came in at -$72.9 million, down 112.02% year-over-year; the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 452.82% YoY), and the FY2024 annual result was -$6.9 million, up 96.61% from the prior year.
- Income towards Parent Company eased to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $34.4 million in Q3 2024 and troughed at -$72.9 million in Q4 2025.
- A 3-year average of -$9.8 million and a median of -$6.8 million in 2025 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company soared 237.26% in 2024, then plunged 119.87% in 2025.
- A 3-year view of Income towards Parent Company shows it stood at -$25.0 million in 2023, then tumbled by 37.26% to -$34.4 million in 2024, then sank by 112.02% to -$72.9 million in 2025.
- Business Quant data shows NBP's Income towards Parent Company at -$72.9 million in Q4 2025, -$6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | 34.36 Mn |
| Jun 30, 2024 | 31.94 Mn |
| Mar 31, 2024 | -6.90 Mn |
| Sep 30, 2023 | -25.04 Mn |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |